

**MINUTES
AREA DRUG AND THERAPEUTICS COMMITTEE
WEDNESDAY 20th JULY 2022 @10am
Microsoft Teams Meeting**

In Attendance:

Dr Mehrdad Malekian	Mrs Karen Patterson	Mrs Katrina Maroni
Mr George Lindsay	Mrs Carol McGoff	Dr Iain Hathorn
Dr David Semple	Dr Tyra Smyth	Mrs Penny Brankin
Mr Michael McLuskey (observer)		

2022/108	1.	<p><u>Apologies for Absence</u></p> <p>Ms Ann Auld, Ms Linda Johnstone, Dr Stephanie Dundas, Mrs Emma Harris, Mr Bill Angus, Mrs Christine Gilmour, Mrs Gail Richardson</p>	
2022/109	2.	<p><u>Declaration of Interest</u></p> <p>There were no declarations of interest.</p>	
2022/110	3.	<p><u>Matters arising not covered elsewhere on the agenda</u></p> <p>a. <u>Ratification of minutes of meeting 16th June 2022</u></p> <p>The minute was accepted as a true record and can now be published.</p> <p>b. <u>Steroid Emergency Cards</u></p> <p>This is ongoing. Dr Malekian will discuss with Mrs Gilmour.</p> <p>c. <u>A guideline for Periprocedure management of coagulation.</u></p> <p>Dr Malekian talked through this guideline and the discussions he had had with Dr Hung. There are some formatting issues to address and Dr Smyth requested that consideration be given to the benefits or otherwise of including the GP component of the following sentence in the “Information for Patients” section.</p> <p>“Don’t stop your anticoagulant drug unless you are instructed to do so by the hospital or your GP.”</p> <p>Dr Malekian will feedback to Dr Hung and agree the final version for publication</p>	<p>IM</p> <p>MM</p> <p>MM</p>

	<p><u>Catheter Directed Thrombolysis</u></p> <p>d. Dr Malekian discussed the update and there was discussion around the following themes:</p> <ul style="list-style-type: none"> • The assuredness of a referral pathway to A&E • The assuredness that a 7 day per week supply of LMWH upon discharge will suffice • Referral routes for GP in out of area practices. <p>There was agreement that these issues are sufficiently robust to approve the protocol and that it can be refined, if necessary, in the light of experience.</p> <p>This can now be published and Dr Malekian will feedback to the author and will sign the blanket use of a medicine outwith its licence form.</p>	MM
2022/111 4.	<p><u>SMC ADVICE</u></p> <p><u>FULL SUBMISSIONS</u></p> <p>Roxadustat (Evrenzo®) SMC2461 This was noted and will be referred to renal specialists.</p> <p>Daratumumab (Darzalex®) SMC2447 This was noted.</p> <p>Atezolizumab (Tecentriq®) SMC2492 This was noted and will be referred to the West of Scotland Cancer Network (WoSCAN).</p> <p>Remimazolam (Byfavo®) SMC2454 This was noted.</p> <p><u>Update on the interim assessment approach in response to COVID-19</u></p> <p>This is a pragmatic approach to minimise delay in patient access as a result of the COVID-19 pandemic. Following review by the SMC executive, SMC advice for one abbreviated submission noted below will be published on the SMC website on Monday 08 August 2022.</p> <p><u>ABBREVIATED SUBMISSION</u></p> <p>Somatrogon (Ngenla®) SMC2493 This was noted and will be referred to paediatrics.</p>	

	<p><u>DEFERRED ADVICE</u></p> <p>Potassium citrate and potassium hydrogen carbonate 8mEq and 24mEq prolonged-release granules (Sibnaya[®]) SMC2409</p> <p>This was noted and will be referred to paediatrics and renal specialists.</p> <p>Beclometasone dipropionate / formoterol fumarate dihydrate / glycopyrronium (Trimbow[®]) SMC2334</p> <p>This was noted and will be referred to respiratory specialists.</p> <p><u>Paediatric Licence Extensions</u></p> <p>These were noted.</p> <p><u>UO Validation</u></p> <p>This was noted.</p>	
2022/112	<p>5. <u>SMC follow up</u></p> <p>Mrs McGoff talked the committee through the SMC follow up which had been previously circulated. Feedback on a number of items is expected in due course.</p>	CMcG
2022/113	<p>6. <u>Lanarkshire Formulary</u></p> <p>a. <u>Formulary amendment request form: Naloxone nasal spray</u></p> <p>This was submitted by the Harm Reduction Service and discussed as below.</p> <p>b. <u>Formulary amendments July 2022</u></p> <p>Mrs McGoff proposed three formulary amendments.</p> <p>The first was regarding the addition of take home naloxone nasal spray (Nyxoid[®]) to the formulary. This remains pending as more information was requested by the Committee on the use of naloxone in urgent care settings and will be brought back to a future meeting in due course.</p> <p>The second was regarding the entry for IV iron preparations, specifically to remove the restriction to use of Ferinject[®] in Obstetrics and Gynaecology, and to add Monofer[®] for restricted use in peri-operative iron optimisation. This was agreed. Prescribing notes have been expanded to include information about extravasation, and it was agreed by the Committee that the prescribing note could be expanded to add that IV iron could be used in preference to oral if there is a short time frame to optimise iron levels for major surgery.</p> <p>The third was the addition of romosozumab and teriparatide as S2 medications, for specialist use only in osteoporosis. The Committee ratified this.</p>	CMcG KM

2022/114	7.	<u>Clinical Protocols</u>	
	a.	<u>Diamorphine</u> These were approved. Mr Lindsay will contact Ms Dunn and also request that the protocols be shared with all three acute sites and consideration be given to inclusion of the protocols within the Induction resource for new staff.	GL
	b.	<u>CD OOH Documents</u> The document was approved save the reference to “Medication used to treat sleep disorders” should be changed to “BNF Chapter 4 Section 7 Sleep Disorders” “”. At the request of Dr Smyth Dr Hathorn will also consider sharing it with other relevant sections of the service including GP Practices. Dr Malekian and Dr Hathorn will also meet to discuss a format suitable for publication via the guideline APP.	IH MM/IH
	c.	<u>Obeticholic Acid Protocol</u> This was agreed and Dr Malekian will feedback to the authors.	MM
	d.	<u>SC Omeprazole</u> On behalf of Mrs Johnstone, Mr Lindsay discussed a request for extension of the current protocol for sc omeprazole with a minor modification. It was agreed that this should be circulated to ADTC members asking for comments by end July.	GL
2022/115	8.	<u>ADTC New Medicines Decisions</u> This was noted.	CMcG
2022/116	9.	<u>Unlicensed Medicines</u> There was nil to report at today’s meeting.	
2022/117	10.	<u>Patient Group Directions</u> <u>Updated template and procedure</u> Mr Lindsay commented upon new revised wording regarding the relative responsibilities of service managers, team leaders and practitioners which should be incorporated into the template and also about alternative approval pathways for vaccination PGDs and those for community pharmacy practice. Both these scenarios are often based upon PGD templates produced for all of Scotland.	

	<p>This was agreed and Mr Lindsay will feed this back at a meeting on Thu 21st July.</p> <p>b. <u>Optometry PGDs</u></p> <p>These are updates of longstanding and effective systems and were agreed. Mr Lindsay will feedback</p>	<p>GL</p> <p>GL</p>
<p>2022/118 11.</p>	<p><u>Medication and Clinical risk in Lanarkshire</u> https://www.gov.uk/drug-safety-update</p> <p>This was noted.</p>	
<p>2022/119 12.</p>	<p><u>Regional Cancer Advisory Network</u></p> <p>There was nil to report at today's meeting.</p>	
<p>2022/120 13.</p>	<p><u>Patient Safety Alerts</u></p> <p>There was nil to report at today's meeting.</p>	
<p>2022/121 14.</p>	<p><u>Lay member related items</u></p> <p>There was nil to report at today's meeting.</p>	
	<p>2022/122 15. <u>ADTCC Correspondence</u></p> <p>a. <u>Abiraterone</u></p> <p>It was noted that this had been discussed by Mrs Gilmour and Mr Milne in advance of the meeting and the implications identified.</p> <p>b. <u>Efgartigimod</u></p> <p>This was noted.</p> <p>c. <u>Advice for primary care regarding prescribing requests following private ADHD diagnosis- for ADHD ratification</u></p> <p>There was a useful discussion in which Dr Semple explained that the document under review was local advice specifically in relation to ADHD.</p> <p>The committee agreed that this is a useful stand-alone document and that it should be published and distributed by the MHL D Committee with that context made clear.</p> <p>Some members felt the document could be used as a template for other specific conditions should similar issues arise as frequently as the queries regarding ADHD private prescriptions.</p> <p>Mr Lindsay will feedback to Ms Templeton and copy in Dr Semple.</p>	<p>GL</p>

2022/123 16.	Pharmacy & NMAHP Prescribing Governance There was nil to note at today's meeting.	PB
2022/124 17.	<u>AOCB</u> Mrs Maroni relayed a summary of items discussed at the July Formulary Network Forum, in particular liraglutide and the application of the new steroid warning cards.	
2022/125 18.	<u>Date of next meeting</u> Wednesday 17 th August 2022 10am @ Microsoft Teams	